Monoamine oxidase and catechol-O-methyltransferase inhibitors (Q33545299)

27 July 2017

1 reference

title

Monoamine oxidase and catechol-O-methyltransferase inhibitors (English)

1 reference

27 July 2017

A Siderowf

1

1 reference

27 July 2017

R Kurlan

series ordinal

2

1 reference

27 July 2017

language of work or name

1 reference

1 March 1999

1 reference

Medical Clinics of North America

27 July 2017

1 reference

27 July 2017

83

1 reference

27 July 2017

2

1 reference

27 July 2017

445-467

1 reference

Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial

27 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Tolcapone and fulminant hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

L-deprenyl as an adjunct to low-dose bromocriptine in early Parkinson's disease: a short-term, double-blind, and prospective follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

(-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

(?)-Deprenyl can induce soluble superoxide dismutase in rat striata

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Modification of Parkinsonism--chronic treatment with L-dopa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Aromatic Amino Acids and Modification of Parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ?cheese effect?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

3-O-methyldopa and motor fluctuations in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Pharmacology of selegiline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Dopamine is a monoamine oxidase B substrate in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

[Oxidation of serotonin and tyramine by rat liver mitochondria]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Dynamic characteristic of the 'functional compartment' of dopamine in dopaminergic terminals of the rat striatum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

The rationale for the use of dopamine agonists in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Distribution of catechol-O-methyltransferase enzyme in rat tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

3-Methoxytyramine Is the Major Metabolite of Released Dopamine in the Rat Frontal Cortex: Reassessment of the Effects of Antipsychotics on the Dynamics of Dopamine Release and Metabolism in the Frontal Cortex, Nucleus Accumbens, and Striatum by a Sim

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Steady plasma levodopa concentrations required for good clinical response to CR-4 in patients with 'on-off'

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Repeated L-dopa administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Selegiline as initial treatment in de novo parkinsonian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Lisuride plus selegiline in the treatment of early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Selegiline: current perspectives on issues related to neuroprotection and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Selegiline and mortality in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

The effect of deprenyl and levodopa on the progression of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Effect of deprenyl on the progression of disability in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Antiparkinsonian therapies and brain mitochondrial complex I activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Deprenyl is metabolized to methamphetamine and amphetamine in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Molecular neuroanatomy of monoamine oxidases in human brainstem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

On the mode of action of L-deprenyl in the human central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

L-deprenyl treatment of on-off phenomena in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Absorption and Metabolism of L-Dopa by the Human Stomach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Dopamine receptor interactions: some implications for the treatment of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Transamination is a Major Pathway of L-Dopa Metabolism following Peripheral Decarboxylase Inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

(-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

The effect of dietary protein on the efficacy of L-dopa: a double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Active Transport of L-Dopa in the Intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Side effects of selegiline (Eldepryl)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Drug Therapy of Parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

Severe adverse interaction between pethidine and selegiline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970113-9

10.1016/S0025-7125(05)70113-9

7 January 2021

Identifiers

DOI

1 reference

release_mvbn7mipyneofmfnrjagyi5w6e

27 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mvbn7mipyneofmfnrjagyi5w6e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference